MUR
50
6
CRM
60
3
GS
80
17
V
66
10
AXP
73
9
MCK
64
7
CMS
54
-3
GWW
76
9
MTB
68
12
NEM
26
-2
USB
54
8
TGT
42
-2
MSFT
51
5
AMG
36
7
CSCO
63
3
FLR
68
8
TRIP
64
3
UNH
61
8
AAPL
37
-9
CNX
75
6
MUR
50
6
CRM
60
3
GS
80
17
V
66
10
AXP
73
9
MCK
64
7
CMS
54
-3
GWW
76
9
MTB
68
12
NEM
26
-2
USB
54
8
TGT
42
-2
MSFT
51
5
AMG
36
7
CSCO
63
3
FLR
68
8
TRIP
64
3
UNH
61
8
AAPL
37
-9
CNX
75
6
Financhill
Back

Phathom Pharmaceuticals 10K Form

Buy
60

PHAT
Phathom Pharmaceuticals

Last Price:
18.52
Seasonality Move:
-6.37%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PHAT News And Ratings

See the #1 stock for the next 7 days that we like better than PHAT

PHAT Financial Statistics

Sales & Book Value

Annual Sales: $682K
Cash Flow: $-70.77M
Price / Cash Flow: 0
Annual Sales: $-3.99
Price / Book: 0

Profitability

EPS (TTM): -5.19000
Net Income (TTM): $-297.11M
Gross Margin: $515K
Return on Equity: 0%
Return on Assets: 0%

Phathom Pharmaceuticals Earnings Forecast

Key Phathom Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PHAT is 75.51%.
  • The Selling, General & Administrative Expenses for PHAT have been equal to 17,291.50% of Gross Profit Margin.
  • The Research & Development expenses have been 7,316.57% of Revenue.
  • The Interest Expense is -20.82% of Operating Income.
  • The Net Earning history of PHAT is -29,558.94% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 2 years.

Phathom Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: PHAT
CUSIP: 71722W
Website: phathompharma.com

Debt

Debt-to-Equity Ratio: -0.75
Current Ratio: 6.48
Quick Ratio: 6.11

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PHAT Technical Analysis vs Fundamental Analysis

Buy
60
Phathom Pharmaceuticals (PHAT) is a Buy

Is Phathom Pharmaceuticals a Buy or a Sell?